Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors
TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
- TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
- "Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
- "Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
- In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.